Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Single-dose intraoperative radiotherapy during lumpectomy for breast cancer: an innovative patient-centred treatment

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A novel homozygous GFI1B variant in 2 sisters with thrombocytopenia and severe bleeding tendency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Direct to consumer genetic testing in Denmark-public knowledge, use, and attitudes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)

    Publikation: Bidrag til tidsskriftReviewpeer review

Vis graf over relationer

BACKGROUND: The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of BRCA2 carriers.

METHODS: We studied 608 women with invasive breast cancer and a pathogenic BRCA2 mutation (variant) from four Nordic countries. Information on prognostic factors and treatment was retrieved from health records and by analysis of archived tissue specimens. Hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression.

RESULTS: About 77% of cancers were ER-positive, with the highest proportion (83%) in patients under 40 years. ER-positive breast cancers were more likely to be node-positive (59%) than ER-negative cancers (34%) (P < 0.001). The survival analysis included 584 patients. Positive ER status was protective in the first 5 years from diagnosis (multivariate HR = 0.49; 95% CI 0.26-0.93, P = 0.03); thereafter, the effect was adverse (HR = 1.91; 95% CI 1.07-3.39, P = 0.03). The adverse effect of positive ER status was limited to women who did not undergo endocrine treatment (HR = 2.36; 95% CI 1.26-4.44, P = 0.01) and patients with intact ovaries (HR = 1.99; 95% CI 1.11-3.59, P = 0.02).

CONCLUSIONS: The adverse effect of a positive ER status in BRCA2 carriers with breast cancer may be contingent on exposure to ovarian hormones.

OriginalsprogEngelsk
TidsskriftBritish Journal of Cancer
Vol/bind123
Udgave nummer11
Sider (fra-til)1608-1615
Antal sider8
ISSN0007-0920
DOI
StatusUdgivet - nov. 2020

ID: 61368879